Xenoport
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | $15.9m | Series A | |
N/A | $2.0m | Grant | |
$43.9m | Series B | ||
$37.0m | Series C | ||
$25.0m | Series D | ||
N/A | N/A | IPO | |
N/A | $20.0m | Late VC | |
N/A | $467m Valuation: $467m | Acquisition | |
Total Funding | AUD222m |
Related Content
Recent News about Xenoport
EditArbor Pharmaceuticals, based in Atlanta, Georgia, is a specialty pharmaceutical company focused on marketing prescription products across various therapeutic areas including cardiovascular, hospital, neuroscience, and pediatric markets. The company is led by a team of experienced pharmaceutical veterans, many of whom have backgrounds as healthcare practitioners, providing them with a deep understanding of the pharmaceutical development process and the value their products bring to patients' lives. Arbor Pharmaceuticals operates in the highly regulated pharmaceutical market, serving healthcare providers and patients who require specialized prescription medications. The business model revolves around the development, marketing, and sale of branded prescription products, with several products currently in late-stage development. Revenue is generated through the sale of these prescription medications to hospitals, clinics, and pharmacies. Arbor Pharmaceuticals aims to improve lives by advancing medicine, leveraging their expertise to bring innovative treatments to market.
Keywords: specialty pharmaceuticals, cardiovascular, hospital, neuroscience, pediatric, prescription products, healthcare practitioners, pharmaceutical development, branded products, innovative treatments.